#PharmaIntelligence #GenericDrugs #RegulatoryAffairs #PharmacodiaGlobal #ChinaPharma #DrugDevelopment To view or add a comment, sign in Canada Adopts ICH M13A Guideline for Some Modified Release (MR) Products Based on: Health Canada's official notice on ICH M13A implementation Link to Notice What is ICH M13A
reported improved glucose tolerance, cardiac contractility, and survival after infusion of exenatide in murine model of dilated cardiomyopathy [52]
However, if cloudiness persists after several minutes, the product may be compromised
GLP-1 therapy involves medications that mimic the glucagon-like peptide-1 hormone, which helps regulate appetite and blood sugar levels
However, you may also experience serious side effects, and you will likely have to keep taking the drug forever because youre not addressing any of the underlying causes behind your weight gain or weight loss resistance
Dietary fiber , especially soluble and fermentable types, represents one of the most robust dietary stimulators of GLP-1 release
